mhGAP: Bridging the Gap for Mental, Neurological, and Substance Use Disorders

The third iteration of the mhGAP guideline has been released to help countries better address the challenges posed by mental, neurological, and substance use (MNS) conditions. This latest edition includes 30 updated recommendations and 18 new ones, in addition to the 90 existing recommendations. The need for improved capacity to tackle MNS conditions is growing, and this guideline aims to provide non-specialist health workers in low and middle-income countries with high-quality, timely, transparent, and evidence-based guidance to effectively treat and care for individuals with these conditions.

Developed over the past 15 years with significant investment in the mhGAP programme, this guideline reflects years of expertise and best practices in the field. The revised recommendations are designed to ensure that mhGAP continues to be a valuable resource for non-specialist health workers who play a critical role in delivering treatment and care for individuals with MNS conditions. By providing clear guidance on diagnosis, treatment, and management of these conditions, mhGAP helps to reduce the treatment gap and improve outcomes for those affected.

Leave a Reply

Previous post Morgan Stanley’s Predictions on CBRT’s Interest Rate Changes
Next post Expert Sir Patrick Vallance Calls for Balanced Approach to Science and Economics in Pandemic Decision-Making